Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 13, 2011

Pharmalink Licenses Archimedes' Targit Enteric Delivery Technology

  • Pharmalink negotiated an exclusive global license to formulate its lead corticosteroid candidate Nefecon® using Archimedes Pharma’s TARGIT® gastrointestinal drug delivery technology. Nefecon is in mid-late stage trials for the treatment of IgA nephropathy, and to date has been codeveloped with Archimedes using the latter’s enteric delivery platform. 

    The firms initiated their codevelopment program for Nefecon in 2004, but the new licensing agreement means that Pharmalink will assume full control and responsibility for further development of the drug. Archimedes will receive an up-front payment, and royalties on future sales of Nefecon. The firm also retains all rights to the TARGIT platform for non-Nefecon applications. An open-label Phase II study with Nefecon has been successfully completed in Sweden, and Pharmalink says pivotal studies are being planned.

    “Our collaboration with Archimedes delivered very strong progress, and having secured an exclusive license to TARGIT we look forward to continuing to drive the development of Nefecon,” comments Johan Haggblad, Pharmalink MD. 

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »